The ETS Inhibitors YK-4-279 and TK-216 Are Novel Antilymphoma Agents

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• Transcription factors, particularly ETS family members, are frequently deregulated in various cancers, including lymphomas.
• Targeting transcription factors is challenging due to their nonenzymatic mechanisms.
• Altered ETS factor expression is a hallmark in numerous tumor types.

Purpose of the Study:

• To investigate the antilymphoma activity of small molecules YK-4-279 and TK-216.
• To characterize the mechanism of action of these agents targeting ETS factors.
• To evaluate their efficacy as single agents and in combination therapies.

Main Methods:

• Preclinical in vitro activity screening across a diverse lymphoma cell line panel.
• In vivo validation studies using relevant lymphoma models.
• Transcriptome analysis and co-immunoprecipitation to elucidate molecular interactions.

Main Results:

• YK-4-279 and TK-216 exhibited significant antitumor activity in multiple lymphoma cell lines, confirmed in vivo.
• Synergistic effects were observed when combined with venetoclax (BCL2 inhibitor) and lenalidomide (immunomodulatory drug).
• These compounds were shown to disrupt protein-protein interactions involving ETS factors SPIB and SPI1 in specific diffuse large B-cell lymphoma subtypes.

Conclusions:

• YK-4-279 and its clinical derivative TK-216 represent a novel class of ETS inhibitors with demonstrated in vitro and in vivo antitumor activity in lymphomas.
• These agents may exert their effects by targeting subtype-specific essential transcription factors in diffuse large B-cell lymphoma (DLBCL).
• Further research is warranted to fully define their mechanism of action and therapeutic potential.